BACKGROUND: At present there is no defined role for routine FDG-PET in the preoperative evaluation of nonmetastatic @entity5 . OBJECTIVE: The primary objective of this study was to evaluate the ability of FDG-PET to predict long-term prognosis based on the response to neoadjuvant chemoradiotherapy in @entity1 with locally advanced @entity5 . DESIGN: This was a prospective study. SETTINGS: This study was performed at an academic, tertiary care, comprehensive @entity5 center. @entity1 : One hundred twenty-seven @entity1 with locally advanced @entity5 were enrolled between September 1999 and December 2005. INTERVENTIONS: All @entity1 underwent FDG-PET scans before and after neoadjuvant chemoradiotherapy. MAIN OUTCOME MEASURES: FDG-PET parameters were evaluated by at least 2 study board-certified nuclear medicine physicians, and included mean standard uptake value, maximum standard uptake value, total lesion glycolysis, and visual response score. The main outcome measures were time to recurrence and disease-specific survival. RESULTS: Of 127 @entity1 , 82 (65%) were @entity1 , the median age was 60 years (range, 27-82), 110 @entity1 had @entity5 , and 17 @entity1 had stage IV disease. Median follow-up among survivors was 77 months (range, 1-115 months). Nine @entity1 had unresectable metastatic disease and were excluded from the time-to-recurrence analysis. At 5 years, 74% (95% CI = 66%-81%) of @entity1 had not had recurrences (locally and/or distantly). The 5-year disease-specific survival was 89% (95% CI = 81%-93%). On univariate analysis, visual response score and time to recurrence came closest to having an association (HR = 0.83, 95% CI = 0.68-1.01, p = 0.06). On multivariate analysis, the visual response score was not significant (p = 0.85). No FDG-PET parameter was associated with disease-specific survival. CONCLUSIONS: Assessment of @entity5 response to neoadjuvant chemoradiotherapy by FDG-PET provides no prognostic information. Therefore, serial FDG-PET before and after neoadjuvant chemoradiotherapy should not be performed for this purpose.

FDG-PET assessment of XXXX response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation.

@entity5 :: ('MESH:D009369', 'Disease') :: ['stage II/III disease', 'cancer', 'rectal cancer'] @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS', 'men']
@entity5 :: (MESH:D009369,Disease) :: ['rectal cancer']
